Will cangrelor become the favored agent for acute coronary syndrome treatment?

Marco Ferlini, Marcello Marino, Luigi Oltrona Visconti, Ezio Bramucci

Research output: Contribution to journalArticlepeer-review


Clopidogrel has been widely investigated, even if resistance limits its efficacy. Prasugrel and ticagrelor obtain a greater and homogeneous inhibition of platelet aggregation, but a delay onset of action in patients with stent thrombosis elevation myocardial infarction and an increased bleeding risk in case of surgical revascularization have been reported. Cangrelor is an intravenous reversible P2Y12 inhibitor with an immediate onset and a quick offset of action. Based on its pharmacokinetic and pharmacodynamic profile, and on clinical data, cangrelor could become the antiplatelet of choice in case of elective percutaneous coronary intervention without clopidogrel pretreatment and in acute coronary syndrome requiring urgent coronary angiography. However, in acute setting, data of comparison with prasugrel and ticagrelor are needed.

Original languageEnglish
Pages (from-to)537-545
Number of pages9
JournalInterventional Cardiology
Issue number6
Publication statusPublished - Dec 1 2014


  • acute coronary syndrome
  • cangrelor
  • P2Y inhibitors
  • platelet inhibition
  • stent thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Will cangrelor become the favored agent for acute coronary syndrome treatment?'. Together they form a unique fingerprint.

Cite this